Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rieko Sekine is active.

Publication


Featured researches published by Rieko Sekine.


British Journal of Haematology | 2002

A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukaemia in complete remission

Jun Ooi; Tohru Iseki; Satoshi Takahashi; Akira Tomonari; Hitomi Nagayama; Koji Ishii; Kiyoshi Ito; Hiroyuki Sato; Tsutomu Takahashi; Motohiro Shindo; Rieko Sekine; Nobuhiro Ohno; Kaoru Uchimaru; Fumitaka Nagamura; Naoki Shirafuji; Arinobu Tojo; Kenzaburo Tani; Shigetaka Asano

Summary.  We performed a clinical comparison of unrelated cord blood transplantation (UCBT) and unrelated bone marrow transplantation in adult acute leukaemia patients in complete remission (CR) who received the same conditioning regimen, graft‐versus‐host disease (GvHD) prophylaxis and supportive treatment. The incidence of acute GvHD was almost the same between the two groups, but the haematopoietic recovery was delayed and the incidence of chronic GvHD was higher in the UCBT group. The probability of 2 year disease‐free survival was similar between the two groups. These results suggest that adult acute leukaemia patients in CR without a suitable donor should be considered as candidates for UCBT.


European Journal of Nuclear Medicine and Molecular Imaging | 2006

In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals.

Yusuke Inoue; Arinobu Tojo; Rieko Sekine; Yasushi Soda; Seiichiro Kobayashi; Akiko Nomura; Kiyoko Izawa; Toshio Kitamura; Toshiyuki Okubo; Kuni Ohtomo

PurposeThe application of in vivo bioluminescence imaging to non-invasive, quantitative monitoring of tumour models relies on a positive correlation between the intensity of bioluminescence and the tumour burden. We conducted cell culture studies to investigate the relationship between bioluminescent signal intensity and viable cell numbers in murine leukaemia model cells.MethodsInterleukin-3 (IL-3)-dependent murine pro-B cell line Ba/F3 was transduced with firefly luciferase to generate cells expressing luciferase stably under the control of a retroviral long terminal repeat. The luciferase-expressing cells were transduced with p190 BCR-ABL to give factor-independent proliferation. The cells were cultured under various conditions, and bioluminescent signal intensity was compared with viable cell numbers and the cell cycle stage.ResultsThe Ba/F3 cells showed autonomous growth as well as stable luciferase expression following transduction with both luciferase and p190 BCR-ABL, and in vivo bioluminescence imaging permitted external detection of these cells implanted into mice. The bioluminescence intensities tended to reflect cell proliferation and responses to imatinib in cell culture studies. However, the luminescence per viable cell was influenced by the IL-3 concentration in factor-dependent cells and by the stage of proliferation and imatinib concentration in factor-independent cells, thereby impairing the proportionality between viable cell number and bioluminescent signal intensity. Luminescence per cell tended to vary in association with the fraction of proliferating cells.ConclusionAlthough in vivo bioluminescence imaging would allow non-invasive monitoring of leukaemia model animals, environmental factors and therapeutic interventions may cause some discrepancies between tumour burden and bioluminescence intensity.


International Journal of Hematology | 2008

Efficient retroviral transduction of human B-lymphoid and myeloid progenitors: marked inhibition of their growth by the Pax5 transgene

Rieko Sekine; Toshio Kitamura; Takashi Tsuji; Arinobu Tojo

We applied a coculture system for the genetic manipulation of human B-lymphoid and myeloid progenitor cells using murine bone marrow stromal cell support, and investigated the effects of forced Pax5 expression in both cell types. Cytokine-stimulated cord blood CD34+ cells could be transduced at 85% efficiency and 95% cell viability by a single 24-h infection with RD114-pseudotyped retroviral vectors, produced by the packaging cell line Plat-F and bicistronic vector plasmids pMXs-Ig, pMYs-Ig, or pMCs-Ig, encoding EGFP. Infected CD34+ cells were seeded onto HESS-5 cells in the presence of stem cell factor and granulocyte colony-stimulating factor, allowing the extensive production of B progenitors and granulocytic cells. We examined the cell number and CD34, CD33, CD19, and CD20 lambda and kappa expressions by flow cytometry. Ectopic expression of Pax5 in CD34+ cells resulted in small myeloid progenitors coexpressing CD33 and CD19 and inhibited myeloid differentiation. After 6 weeks, the number of Pax5-transduced CD19+ cells was 40-fold lower than that of control cells. However, the expression of CD20 and the κ/λ chain on Pax5-transduced CD19+ cells suggests that the Pax5 transgene may not interfere with their differentiation. This report is the first to describe the effects of forced Pax5 expression in human hematopoietic progenitors.


International Journal of Hematology | 2005

Atypical Hypersensitivity to Mosquito Bites without Natural Killer Cell Proliferative Disease in an Adult Patient

Takaaki Konuma; Kaoru Uchimaru; Rieko Sekine; Nobuhiro Ohno; Yasushi Soda; Akira Tomonari; Jun Ooi; Fumitaka Nagamura; Satoshi Takahashi; Tohru Iseki; Naoki Oyaizu; Arinobu Tojo; Shigetaka Asano

Hypersensitivity to mosquito bites (HMB) is a rare disorder that occurs in the first 2 decades of life and is considered to be associated with chronic Epstein-Barr virus (EBV) infection and natural killer (NK) cell leukemia/lymphoma. EBV-encoded small nuclear RNA (EBER)-positive NK cells infiltrate the skin lesion at the site of the mosquito bite. In this report, we present the case of an adult patient with mantle cell lymphoma complicated by atypical HMB. The anti-EBV antibody titer of the patient indicated reactivation of chronic infection with this virus, and EBV DNA in the peripheral blood mononuclear cells was detected after chemotherapy by quantitative polymerase chain reaction analysis. However, an in situ hybridization analysis did not detect EBER-positive cells in the skin lesion at the bite site or in the lymph node. Peripheral NK cell lymphocytosis and EBV-associated lymphoproliferative disease did not develop. These findings suggest that some patients with chronic EBV infection may develop HMB without NK cell proliferative disease.


Molecular Imaging | 2006

Light emission requires exposure to the atmosphere in ex vivo bioluminescence imaging.

Yusuke Inoue; Kiyoko Izawa; Arinobu Tojo; Rieko Sekine; Toshiyuki Okubo; Kuni Ohtomo

The identification of organs bearing luciferase activity by in vivo bioluminescence imaging (BLI) is often difficult, and ex vivo imaging of excised organs plays a complementary role. This study investigated the importance of exposure to the atmosphere in ex vivo BLI. Mice were inoculated with murine pro-B cell line Ba/F3 transduced with firefly luciferase and p190 BCR-ABL. They were killed following in vivo BLI, and whole-body imaging was done after death and then after intraperitoneal air injection. In addition, the right knee was exposed and imaged before and after the adjacent bones were cut. Extensive light signals were seen on in vivo imaging. The luminescence disappeared after the animal was killed, and air injection restored the light emission from the abdomen only, suggesting a critical role of atmospheric oxygen in luminescence after death. Although no substantial light signal at the right knee was seen before bone cutting, light emission was evident after cutting. In conclusion, in ex vivo BLI, light emission requires exposure to the atmosphere. Bone destruction is required to demonstrate luciferase activity in the bone marrow after death.


The Japanese journal of clinical hematology | 2015

The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma

Junko Inoue; Masahiro Ikeda; Sumito Shingaki; Kanji Miyazaki; Sosuke Meshitsuka; Yu Abe; Rieko Sekine; Nobuhiro Tsukada; Yutaka Hattori; Kenshi Suzuki

CD138 has been considered to be strongly expressed in multiple myeloma cells. However, CD138⁺ cells were decreased in some patients during the course of treatment. To clarify the clinical significance of this finding, we evaluated the correlations of CD138 levels with laboratory data employing flow cytometry. We found that CD138⁺ cells were decreased in 12 patients during treatment and were retained in the remaining 105 patients throughout their clinical courses. For nine (75%) patients in the CD138⁺ cells reduced group, median survival time was 25 months after the reduction in CD138⁺ cells was detected, and all nine died of myeloma. Furthermore, extramedullary lesions and specific cytogenetic abnormalities [del(17p), t(4;14), amplification of c-MYC] were observed in some patients when the number of CD138⁺ cells started to decrease. Interestingly, 2 of 3 patients who survived until the end of observation period showed re-increase in their CD138⁺ levels. Taking these observations together, it is unclear whether reduction of the number of CD138⁺ cells is associated with a poor prognosis and resistance to drugs. However, if treatment does not produce a reincrease in CD138⁺ levels, long term survival might be difficult to achieve.


Experimental Hematology | 2007

Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy.

Yusuke Inoue; Kiyoko Izawa; Arinobu Tojo; Yukihiro Nomura; Rieko Sekine; Naoki Oyaizu; Kuni Ohtomo


Immunology Letters | 2007

Identification and comparative analysis of Pax5 C-terminal isoforms expressed in human cord blood-derived B cell progenitors

Rieko Sekine; Toshio Kitamura; Takashi Tsuji; Arinobu Tojo


Blood | 2012

Sustained Molecular Response with Maintenance Dose of Interferon Alfa After Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia

Kensuke Usuki; Nozomi Yusa; Akira Hangaishi; Rieko Sekine; Kenshi Suzuki; Shinya Kimura; Arinobu Tojo


The Japanese journal of clinical hematology | 2014

Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia

Airi Hamano; Sumito Shingaki; Yu Abe; Kanji Miyazaki; Rieko Sekine; Yasunori Nakagawa; Nobuhiro Tsukada; Yutaka Hattori; Kenshi Suzuki

Collaboration


Dive into the Rieko Sekine's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kenshi Suzuki

Memorial Hospital of South Bend

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yasunori Nakagawa

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Takashi Tsuji

Tokyo University of Science

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sumito Shingaki

Tokyo Medical and Dental University

View shared research outputs
Researchain Logo
Decentralizing Knowledge